Related Experiment Video

Updated: Sep 6, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

Synthetic Vulnerabilities in the KRAS Pathway

Marta Roman1, Elizabeth Hwang1, E Alejandro Sweet-Cordero1

  • 1Department of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA.

Cancers
|June 24, 2022
PubMed

Insights

Targeting KRAS-mutant cancers requires new strategies. This review explores synthetic lethal vulnerabilities and stress response pathways for novel therapeutic approaches in KRAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS mutations are common in human cancers, driving oncogenesis through sustained signaling.
  • Targeted therapies for KRAS-mutant cancers are emerging but remain an unmet clinical need.
  • Synthetic lethality offers a promising avenue for developing novel cancer treatments.

Purpose of the Study:

  • To review the concept of synthetic lethal vulnerabilities in KRAS-mutant cancers.
  • To discuss the role of stress response pathways in KRAS-driven oncogenesis.
  • To highlight the potential of exploiting these pathways for therapeutic benefit.

Main Methods:

  • Review of current literature on KRAS mutations and targeted therapies.
  • Analysis of functional genomics data and cancer models.
  • Exploration of molecular pathways involved in KRAS signaling and stress responses.

Main Results:

  • KRAS-driven cancers exhibit unique vulnerabilities exploitable through synthetic lethality.
  • Stress response pathways are activated in KRAS-mutant cells, presenting therapeutic targets.
  • Advances in genomics and modeling reveal new synthetic lethal interactions.

Conclusions:

  • Synthetic lethal interactions represent a promising strategy for treating KRAS-mutant cancers.
  • Targeting stress response pathways offers a novel therapeutic approach.
  • Further research into these vulnerabilities could lead to effective clinical treatments.
Keywords:
KRAScancersynthetic lethality

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K